Skip to main content

CytoMed Therapeutics Ltd

GDTC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001873093

In the last 90 days, CytoMed Therapeutics Ltd insiders filed 1 open-market purchase and 0 sales; 3 institutions reported holding it in 13F filings for Q2 2026, worth $12.2K in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding CytoMed Therapeutics Ltd changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of GDTC: Q4 2025 compared with Q1 2026
MeasureQ4 2025Q1 2026Change
Holders53−2
Shares53.1K16.3K−36.8K (−69.2%)
Value$70.8K$16.3K−$54.4K (−76.9%)

New holders (1)

Institutions that held CytoMed Therapeutics Ltd at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to GDTC in Q1 2026
InstitutionSharesValue% of portfolio
XTX Topco Ltd10,136$10.1K0.00%

Sold out (3)

Institutions that held CytoMed Therapeutics Ltd at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of GDTC in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Susquehanna International Group, LLP29,829$39.7K
Two Sigma Securities, LLC11,857$15.8K
StoneX Group Inc.10,356$13.8K